A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus

Vaccine

Volumn 26, Issue 51, 2008, Pages 6678-6684

  Schulze, Kai ^a   Staib, Caroline ^b,c   Schätzl, Hermann M ^b   Ebensen, Thomas ^a   Erfle, Volker ^b,c   Guzman, Carlos A ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Adjuvant; Modified Vaccinia virus Ankara; Mucosal immunization; Prime boost; SARS

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 2; INTERLEUKIN 4; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; MODIFIED VACCINIA VIRUS ANKARA VACCINE; NUCLEOCAPSID PROTEIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOGENICITY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SPLEEN CELL; VACCINE PRODUCTION; VIRUS NUCLEOCAPSID;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN A; INJECTIONS, INTRAMUSCULAR; LIPOPEPTIDES; MICE; MICE, INBRED BALB C; NUCLEOCAPSID PROTEINS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINIA VIRUS; VIRAL VACCINES;

EID: 58149127668     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.006     Document Type: Article

References (43)

1. Chan-Yeung M., and Yu W.C. Outbreak of severe acute respiratory syndrome in Hong Kong Special Administrative Region: case report. BMJ 326 7394 (April) (2003) 850-852
2. Lew T.W., Kwek T.K., Tai D., Earnest A., Loo S., Singh K., et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 290 3 (July) (2003) 374-380
3. Riley S., Fraser C., Donnelly C.A., Ghani A.C., Abu-Raddad L.J., Hedley A.J., et al. Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions. Science 300 5627 (June) (2003) 1961-1966
4. Yu I.T., Li Y., Wong T.W., Tam W., Chan A.T., Lee J.H., et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 350 17 (April) (2004) 1731-1739
5. Chan-Yeung M., and Xu R.H. SARS: epidemiology. Respirology 8 Suppl (November) (2003) S9-14
6. Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289 21 (June) (2003) 2801-2809
7. Hui D.S., Wong P.C., and Wang C. SARS: clinical features and diagnosis. Respirology 8 Suppl (November) (2003) S20-S24
8. Yang Z.Y., Kong W.P., Huang Y., Roberts A., Murphy B.R., Subbarao K., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 6982 (April) (2004) 561-564
9. He Y., Zhou Y., Siddiqui P., and Jiang S. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun 325 2 (December) (2004) 445-452
10. Xiong S., Wang Y.F., Zhang M.Y., Liu X.J., Zhang C.H., Liu S.S., et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett 95 2 (September) (2004) 139-143
11. Cavanagh D. Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus. Avian Pathol 32 6 (December) (2003) 567-582
12. Seo S.H., Wang L., Smith R., and Collisson E.W. The carboxyl-terminal 120-residue polypeptide of infectious bronchitis virus nucleocapsid induces cytotoxic T lymphocytes and protects chickens from acute infection. J Virol 71 10 (October) (1997) 7889-7894
13. Wesseling J.G., Godeke G.J., Schijns V.E., Prevec L., Graham F.L., Horzinek M.C., et al. Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. J Gen Virol 74 Pt 10 (October) (1993) 2061-2069
14. Wasmoen T.L., Kadakia N.P., Unfer R.C., Fickbohm B.L., Cook C.P., Chu H.J., et al. Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus. Adv Exp Med Biol 380 (1995) 221-228
15. Hornemann S., Harlin O., Staib C., Kisling S., Erfle V., Kaspers B., et al. Replication of modified Vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J Virol 77 15 (August) (2003) 8394-8407
16. Staib C., and Sutter G. Live viral vectors: Vaccinia virus. Methods Mol Med 87 (2003) 51-68
17. Rharbaoui F., Drabner B., Borsutzky S., Winckler U., Morr M., Ensoli B., et al. The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur J Immunol 32 10 (October) (2002) 2857-2865
18. Borsutzky S., Ebensen T., Link C., Becker P.D., Fiorelli V., Cafaro A., et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 24 12 (March) (2006) 2049-2056
19. Medina E., Talay S.R., Chhatwal G.S., and Guzman C.A. Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route. Eur J Immunol 28 3 (1998) 1069-1077
20. Schulze K., Olive C., Ebensen T., and Guzman C.A. Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes. Vaccine 24 35-36 (August) (2006) 6088-6095
21. Kaiser-Schulz G., Heit A., Quintanilla-Martinez L., Hammerschmidt F., Hess S., Jennen L., et al. Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses. J Immunol 179 5 (September) (2007) 2797-2807
22. Diemer C., Schneider M., Seebach J., Quaas J., Frosner G., Schatzl H.M., et al. Cell type-specific cleavage of nucleocapsid protein by effector caspases during SARS coronavirus infection. J Mol Biol 376 1 (February) (2008) 23-34
23. Chen Z., Zhang L., Qin C., Ba L., Yi C.E., Zhang F., et al. Recombinant modified Vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 79 5 (March) (2005) 2678-2688
24. Callendret B., Lorin V., Charneau P., Marianneau P., Contamin H., Betton J.M., et al. Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS. Virology 363 2 (July) (2007) 288-302
25. Pei H., Liu J., Cheng Y., Sun C., Wang C., Lu Y., et al. Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. Appl Microbiol Biotechnol 68 2 (August) (2005) 220-227
26. Okada M., Takemoto Y., Okuno Y., Hashimoto S., Yoshida S., Fukunaga Y., et al. The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. Vaccine 23 1718 (March) (2005) 2269-2272
27. Zhao P., Cao J., Zhao L.J., Qin Z.L., Ke J.S., Pan W., et al. Immune responses against SARS-coronavirus nucleocapsid protein induced by DNA vaccine. Virology 331 1 (January) (2005) 128-135
28. Zhu M.S., Pan Y., Chen H.Q., Shen Y., Wang X.C., Sun Y.J., et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol Lett 92 3 (April) (2004) 237-243
29. Kim T.W., Lee J.H., Hung C.F., Peng S., Roden R., Wang M.C., et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 78 9 (May) (2004) 4638-4645
30. Zakhartchouk A.N., Viswanathan S., Mahony J.B., Gauldie J., and Babiuk L.A. Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice. J Gen Virol 86 Pt 1 (January) (2005) 211-215
31. Weingartl H., Czub M., Czub S., Neufeld J., Marszal P., Gren J., et al. Immunization with modified Vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78 22 (November) (2004) 12672-12676
32. Czub M., Weingartl H., Czub S., He R., and Cao J. Evaluation of modified Vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23 17-18 (March) (2005) 2273-2279
33. Brave A., Gudmundsdotter L., Gasteiger G., Hallermalm K., Kastenmuller W., Rollman E., et al. Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology. Infect Agent Cancer 2 (2007) 14
34. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified Vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 8 (April) (2004) 3930-3940
35. Hodge J.W., Poole D.J., Aarts W.M., Gomez Y.A., Gritz L., and Schlom J. Modified Vaccinia virus Ankara recombinants are as potent as Vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 63 22 (November) (2003) 7942-7949
36. Hanke T., Barnfield C., Wee E.G., Agren L., Samuel R.V., Larke N., et al. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84 Pt 2 (February) (2003) 361-368
37. Nicholls J.M., Butany J., Poon L.L., Chan K.H., Beh S.L., Poutanen S., et al. Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. PLoS Med 3 2 (February) (2006) e27
38. See R.H., Zakhartchouk A.N., Petric M., Lawrence D.J., Mok C.P.Y., Hogan R.J., et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 87 3 (March) (2006) 641-650
39. Bisht H., Roberts A., Vogel L., Bukreyev A., Collins P.L., Murphy B.R., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated Vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101 17 (April) (2004) 6641-6646
40. Pletz M.W., Dickgreber N., Hagen L., Golpon H., Zabel P., Bauer T.T., et al. Immunisation strategies for the management of severe acute respiratory syndrome (SARS). Pneumologie 61 10 (October) (2007) 663-667
41. Vlasova A.N., Zhang X., Hasoksuz M., Nagesha H.S., Haynes L.M., Fang Y., et al. Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein. J Virol 81 24 (December) (2007) 13365-13377
42. Xie J., Han Y., Li T.S., Qiu Z.F., Ma X.J., Fan H.W., et al. Dynamic changes of plasma cytokine levels in patients with severe acute respiratory syndrome. Zhonghua Nei Ke Za Zhi 42 9 (September) (2003) 643-645
43. Beijing Group of National Research Project for SARS. Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin Med J (Engl) 2003;116(9 (September)):1283-7.